AbbVie Inc. $ABBV Stock Bought by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 42.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 59,950 shares of the company’s stock after purchasing an additional 17,870 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in AbbVie were worth $15,682,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. DecisionMap Wealth Management LLC grew its holdings in shares of AbbVie by 3.2% in the third quarter. DecisionMap Wealth Management LLC now owns 1,207 shares of the company’s stock worth $316,000 after purchasing an additional 37 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in AbbVie by 1.3% during the 3rd quarter. Bell Investment Advisors Inc now owns 3,809 shares of the company’s stock valued at $996,000 after buying an additional 48 shares during the last quarter. Verus Financial Partners Inc. raised its holdings in AbbVie by 1.7% during the 3rd quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after buying an additional 35 shares during the last quarter. Columbia Bank boosted its position in AbbVie by 9.9% during the 3rd quarter. Columbia Bank now owns 2,518 shares of the company’s stock valued at $659,000 after buying an additional 227 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in AbbVie in the 3rd quarter worth $140,729,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 0.0%

NYSE ABBV opened at $294.80 on Monday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $298.74. The firm has a market capitalization of $520.85 billion, a PE ratio of 50.74, a P/E/G ratio of 1.35 and a beta of 0.24. The stock’s 50 day moving average is $269.35 and its 200 day moving average is $237.23.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.86 earnings per share. On average, research analysts anticipate that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio is 119.10%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Morgan Stanley boosted their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. UBS Group reiterated a “neutral” rating and issued a $295.00 price objective on shares of AbbVie in a research report on Monday. Rothschild & Co Redburn boosted their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. HSBC upped their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Citigroup lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $282.00.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.